RU2600798C2 - Композиции вакцин и способы их применения - Google Patents

Композиции вакцин и способы их применения Download PDF

Info

Publication number
RU2600798C2
RU2600798C2 RU2011144089/15A RU2011144089A RU2600798C2 RU 2600798 C2 RU2600798 C2 RU 2600798C2 RU 2011144089/15 A RU2011144089/15 A RU 2011144089/15A RU 2011144089 A RU2011144089 A RU 2011144089A RU 2600798 C2 RU2600798 C2 RU 2600798C2
Authority
RU
Russia
Prior art keywords
dendrimer
peptide
antigen
padre
helper
Prior art date
Application number
RU2011144089/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011144089A (ru
Inventor
Пируз Мохаммад ДАФТАРИАН
Паоло СЕРАФИНИ
Вэнс Пол ЛЕММОН
Вэй Ли
Эйнджел КЕЙФЕР
Бонни Бет БЛОМБЕРГ
Виктор Л. ПЕРЕС
Original Assignee
Юниверсити Оф Майами
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Майами filed Critical Юниверсити Оф Майами
Publication of RU2011144089A publication Critical patent/RU2011144089A/ru
Application granted granted Critical
Publication of RU2600798C2 publication Critical patent/RU2600798C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2011144089/15A 2009-04-01 2010-04-01 Композиции вакцин и способы их применения RU2600798C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16573209P 2009-04-01 2009-04-01
US61/165,732 2009-04-01
PCT/US2010/029694 WO2010115046A2 (en) 2009-04-01 2010-04-01 Vaccine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016137258A Division RU2016137258A (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Publications (2)

Publication Number Publication Date
RU2011144089A RU2011144089A (ru) 2013-05-10
RU2600798C2 true RU2600798C2 (ru) 2016-10-27

Family

ID=42828943

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016137258A RU2016137258A (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения
RU2011144089/15A RU2600798C2 (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016137258A RU2016137258A (ru) 2009-04-01 2010-04-01 Композиции вакцин и способы их применения

Country Status (9)

Country Link
US (2) US9764012B2 (https=)
EP (1) EP2413964B1 (https=)
JP (4) JP5661735B2 (https=)
CN (2) CN107050440B (https=)
AU (1) AU2010232512B2 (https=)
BR (1) BRPI1016133A2 (https=)
CA (1) CA2756996C (https=)
RU (2) RU2016137258A (https=)
WO (1) WO2010115046A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
CN110542754A (zh) * 2009-05-19 2019-12-06 迈阿密大学 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
WO2013034741A1 (en) * 2011-09-07 2013-03-14 Midatech Limited Nanoparticle tumour vaccines
EP2753360B1 (en) * 2011-09-07 2017-04-26 Midatech Ltd Nanoparticle-peptide compositions
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2840997A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
HK1213638A1 (zh) * 2013-03-15 2016-07-08 University Of Miami 免疫增強藥物的納米載體
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP2016535060A (ja) * 2013-08-27 2016-11-10 ドイチェス クレブスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 細胞傷害性ｔ細胞応答の修飾物質
WO2015054639A1 (en) * 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus vaccines
WO2015116568A2 (en) * 2014-01-28 2015-08-06 University Of Miami Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017053851A1 (en) * 2015-09-23 2017-03-30 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
CA3024705A1 (en) * 2016-05-23 2017-11-30 University Of Miami Compositions for selective humoral responses and methods of use thereof
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
SG11201911430PA (en) * 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EP3743526B1 (en) 2018-01-28 2025-03-12 Enable Biosciences Inc. Reagents and methods for blocking non-specific interactions with nucleic acids
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN110448695B (zh) * 2019-08-23 2021-07-27 中山大学肿瘤防治中心 一种mRNA疫苗递送载体及其制备方法
WO2022197977A1 (en) * 2021-03-17 2022-09-22 Northwestern University Dendritic peptide conjugated polymers for efficient intracellular delivery of nucleic acids to immune cells
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043677A1 (en) * 1997-03-27 1998-10-08 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023A (en) * 1843-03-30 peters
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US20050169900A1 (en) 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
US6864060B1 (en) * 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
DE69435171D1 (de) * 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
CA2184132C (en) 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
US6201250B1 (en) * 1997-08-22 2001-03-13 Richard C. Morlock Sensor housing for UV curing chamber
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US6632435B1 (en) 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
WO2003025569A1 (en) 2001-09-18 2003-03-27 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
IL161708A0 (en) 2001-11-16 2004-09-27 Pharmexa As Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
WO2003075951A2 (en) 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20080268457A1 (en) 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
CN1809379A (zh) 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
CN101506266A (zh) 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US7358231B1 (en) 2005-12-01 2008-04-15 Applera Corporation Pancreatic cancer secreted targets and uses thereof
US8954355B2 (en) * 2006-01-26 2015-02-10 Psi Systems, Inc. Integrated postage and shipping label system
WO2007089607A2 (en) 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101711360A (zh) 2007-03-16 2010-05-19 赛乐思迪斯有限公司 细胞介导的免疫应答检验及其试剂盒
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043677A1 (en) * 1997-03-27 1998-10-08 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOAS U, HEEGAARD. P. M. H. Dendrimers in drug research. Chem. Soc. Rev., Critical Review. 2004, 33, PP. 43-63. GRAHAM B. S. New Approaches to Vaccine Adjuvants: Inhibiting the Inhibitor. PLOS MED vol. 3, no. 1, 2006, РР. 18 - 20. LO-MAN R. et al. A Fully Synthetic Therapeutic Vaccine Candidate Targeting Carcinoma-Associated Tn Carbohydrate Antigen Induces Tumor-Specific Antibodies in Nonhuman Primates. CANCER RESEARCH 64, July 15, 2004, PP. 4987-499. *

Also Published As

Publication number Publication date
CN102448491A (zh) 2012-05-09
RU2016137258A (ru) 2018-12-13
RU2011144089A (ru) 2013-05-10
BRPI1016133A2 (pt) 2016-04-19
CA2756996A1 (en) 2010-10-07
EP2413964B1 (en) 2019-11-13
US9764012B2 (en) 2017-09-19
EP2413964A2 (en) 2012-02-08
CN107050440B (zh) 2021-10-29
AU2010232512B2 (en) 2013-07-18
JP2016188222A (ja) 2016-11-04
EP2413964A4 (en) 2013-12-25
WO2010115046A3 (en) 2010-11-25
JP5661735B2 (ja) 2015-01-28
AU2010232512A1 (en) 2011-10-27
JP2017165755A (ja) 2017-09-21
RU2016137258A3 (https=) 2020-02-19
JP6321261B2 (ja) 2018-05-09
US20120093761A1 (en) 2012-04-19
JP2015096520A (ja) 2015-05-21
US20180099032A1 (en) 2018-04-12
CA2756996C (en) 2018-12-11
JP6139000B2 (ja) 2017-05-31
JP2012522802A (ja) 2012-09-27
WO2010115046A2 (en) 2010-10-07
CN107050440A (zh) 2017-08-18
AU2010232512A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
RU2600798C2 (ru) Композиции вакцин и способы их применения
JP7535489B2 (ja) 治療用抗癌ネオエピトープワクチン
EP2432893B1 (en) Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
Mattner et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens
Maeta et al. Vitamin E scaffolds of pH-responsive lipid nanoparticles as DNA vaccines in cancer and protozoan infection
Chan et al. PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration
JP7665205B2 (ja) ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種
Deloizy et al. The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skin
US20260014250A1 (en) Immunoconjugate
AU2016201691B2 (en) Vaccine compositions and methods of use thereof
AU2013245442A1 (en) Vaccine compositions and methods of use thereof
Zhang et al. Adjuvant Delivery Method and Nanoparticle Charge Influence Peptide Amphiphile Micelle Vaccine Bioactivity
US20220023421A1 (en) Methods for eliciting selective humoral responses

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210402